Noopept (omberacetam; GVS-111) vs semax
Noopept (omberacetam; GVS-111) (B-tier) vs semax (B-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.
Noopept (omberacetam; GVS-111) — tier B
a Russian cognitive drug with one small active-comparator clinical study, a short human PK poster, substantial animal work, and major US supplement-identity problems.
Noopept has a real foreign-drug identity and limited human data, but the efficacy record is much smaller than its reputation and the US supplement market adds a separate product-quality failure.
53 participants in the main indexed active-comparator study · half-life 22.05 plus or minus 14.37 minutes in a sparsely reported human conference abstract · focus
semax — tier B
russian nootropic. approved there, not here. for focus, stroke recovery, and cognitive decline. real mechanism, thin US trials.
Russian nootropic. approved there since the 1990s. BDNF upregulation within 30 minutes of an intranasal dose, effect persists 24+ hours.
Russia '82 stroke registry · half-life minutes in plasma; effects persist for hours due to CNS penetration and BDNF induction cascade · focus
at a glance
- Noopept (omberacetam; GVS-111): tier B · 53 participants in the main indexed active-comparator study
- semax: tier B · Russia '82 stroke registry
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.
